Dexcom has obtained European approval for the latest generation of its wearable diabetes sensor, the G7 continuous glucose monitor, for adults and children ages two and up. Designed to be 60% smaller ...
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will ...
This week, Tandem Diabetes Care’s t:slim X2 insulin pump and Control-IQ algorithm made headlines as they became the first to integrate with Dexcom’s G7 sensor to create an artificial pancreas system.
DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025. With ...
While still a couple of years out, MD+DI gained some insights into Dexcom's next-generation sensor from an interview with the ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The 15-day Dexcom G7 had a MARD of 8%, a small ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The FDA has granted clearance to a next-generation ...
Dexcom G7 15 Day will first be available through durable medical equipment (DME) providers with full retail launch in the coming weeks. Designed to provide real-time glucose readings for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback